Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. Oncology
Journal of Clinical Oncology2008Vol. 26(35), pp. 5755–5760
Citations Over TimeTop 1% of 2008 papers
Nasser H. Hanna, Marcus A. Neubauer, Constantin T. Yiannoutsos, Ronald C. McGarry, James C. Arseneau, Rafat Ansari, Craig H. Reynolds, Ramaswamy Govindan, Anton Melnyk, William B. Fisher, Donald Richards, Daniel Bruetman, Thomas Anderson, N. M. Chowhan, Sreenivasa Nattam, Prasad Mantravadi, Cynthia S. Johnson, Tim Breen, Angela White, Lawrence Einhorn
Abstract
Consolidation docetaxel after PE/XRT results in increased toxicities but does not further improve survival compared with PE/XRT alone in patients with stage III inoperable NSCLC.
Related Papers
- Docetaxel (Taxotere): preclinical and general clinical information.(1999)
- → Ototoxicity in patients with invasive ductal breast cancer who were treated with docetaxel: report of two cases(2020)12 cited
- → The plinabulin/docetaxel combination to mitigate the known safety concerns of docetaxel.(2016)3 cited
- → Docetaxel (Taxotere) in the Treatment of Non-Small Cell Lung Cancer(2002)18 cited
- TS-1 による術後補助療法中に発症しWeekly Docetaxel 療法により著効をみた胃癌腹膜播種の1 例(2005)